Advertisement

Pulmatrix Inc., a Lexington biotechnology company focused on respiratory diseases, has taken in $14 million in a Series B1 funding round, from all previous including Polaris Venture Partners, 5AM Ventures, Arch Venture Partners, and Novartis Venture Fund.

According to a press release by the company, Pulmatrix will use the new funds to speed up getting its lead iCALM drug candidate, PUR118, through Phase 2A efficacy studies in a pair of diseases - chronic obstructed pulmonary disease (COPD) and cystic fibrosis (CF).

SOURCE

Advertisement
Advertisement